Harvard bioscience posts q4 adjusted eps of $0.08

Harvard bioscience announces fourth quarter 2019 financial results.q4 adjusted earnings per share $0.08.q4 earnings per share $0.01.q4 revenue $31 million versus refinitiv ibes estimate of $31.8 million.q4 earnings per share estimate $0.09 -- refinitiv ibes data.restructuring program is expected to be completed by end of 2020.expect low single digit revenue growth for year.expect low single digit revenue growth for 2020.plan to continue to pay down debt to below 3 times leverage by end of first half of 2020.expects to incur costs associated with headcount reductions, others totaling $4 million to $5 million.expect majority of restructuring activities completed in h1 2020.plan to explore refinancing existing debt to a lower interest rate.
HBIO Ratings Summary
HBIO Quant Ranking